SCHEMBL17100743

SCHEMBL17100743

Clc1ccc(Cc2noc(N3CCN(Cc4ccccc4Cl)CC3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
KDM4E B2RXH2 4/20 0.56
MAPT P10636 4/20 0.56
GAA P10253 2/20 0.56
PLA2G1B P04054 1/20 0.50
RAB9A P51151 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
HTT P42858 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
LMNA P02545 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP2A13 Q16696 1/20 0.45
CXCR4 P61073 1/20 0.45
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100623 0.90 KMT2A (0.57) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL17100858 0.90 LMNA (0.57) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL17100819 0.84 MAPT (0.47) ALDH1A1KDM4EMAPTRAB9ASMN1; SMN2
SCHEMBL17100793 0.82 HTR6 (0.45) ALDH1A1KDM4EMAPTGAARAB9A
SCHEMBL17100749 0.82 L3MBTL1 (0.43) RAB9AHTTSIGMAR1L3MBTL1HTR2A
SCHEMBL17100670 0.82 L3MBTL1 (0.43) RAB9AHTTSIGMAR1L3MBTL1HTR2A
SCHEMBL17100725 0.81 NPC1 (0.43) ALDH1A1MAPTRAB9AHTTSIGMAR1
SCHEMBL17100612 0.81 HTT (0.55) ALDH1A1KDM4EMAPTSMN1; SMN2HTT
SCHEMBL17100729 0.81 HTT (0.55) ALDH1A1KDM4EMAPTSMN1; SMN2HTT
SCHEMBL17100661 0.81 LMNA (0.55) ALDH1A1KDM4EMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT ALDH1A1 482/4885KDM4E 4760/4885MAPT 3/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT ALDH1A1 561/4885KDM4E 4743/4885MAPT 3/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT ALDH1A1 482/4885KDM4E 4760/4885MAPT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.